Goldman Sachs Maintains Neutral Rating for GoodRx Holdings: Here's What You Need To Know

Goldman Sachs has decided to maintain its Neutral rating of GoodRx Holdings GDRX and lower its price target from $7.00 to $6.25.

Shares of GoodRx Holdings are trading up 2.19% over the last 24 hours, at $4.91 per share.

A move to $6.25 would account for a 27.42% increase from the current share price.

About GoodRx Holdings

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers other healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.